clinical trial · NCT07107932
A Registry： Siltartoxatug Injection for Tetanus Prophylaxis Following Injury
Zhuhai Trinomab Pharmaceutical Co., Ltd.·—·recruiting·n = 10,000
TetanusSiltartoxatug Injection (Brand name: Sintetol®)
brief summary
The injury and wound conditions of the enrolled patients will be documented. A follow-up at 90 days post-administration will determine the clinical outcome of tetanus prophylaxis, specifically whether tetanus occurred. The registry will also employ selective safety data collection to record adverse reactions and serious adverse events following Siltartoxatug adminstration.
started
Jul 31, 2025
primary completion
Mar 30, 2029
completion
Mar 30, 2029
last updated
Jan 6, 2026
official title
A Large-Sample Real-World Dynamic Cohort Registry: Observing the Clinical Outcomes of Siltartoxatug Injection for Tetanus Prophylaxis Following Injury
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol